Examination of Efficacy and Safety of Baricitinib in RA Patients

Efficacy and Safety of Baricitinib in Rheumatoid Arthritis Patients Compared With Those Treated by Biologics or Tofacitinib

The aim of this study is to examine the efficacy and adverse events in the following 3 groups in rheumatoid arthritis patients:

1. Baricitinib treatment for 12 months
2. Biologics treatment for 12 months
3. Tofacitinib treatment for 12 months

Inclusion Criteria:

• RA patients

Exclusion Criteria:

• Not RA patients
• RA patients who are allergic to the drugs, refused to do this research, or who are pregnant